GH Research PLC logo

GH Research PLC

NASDAQ:GHRS

Overview | Financials
Company Name GH Research PLC
Symbol GHRS
Currency USD
Price 8.3
Market Cap 431,833,230
Dividend Yield 0%
52-week-range 5.05 - 14.99
Industry Biotechnology
Sector Healthcare
CEO Dr. Theis Terwey M.D.
Website https://www.ghres.com

An error occurred while fetching data.

About GH Research PLC

GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed

Related Stocks

PetIQ, Inc. logo

PetIQ, Inc.

PETQ

30.68 USD

Computer Programs and Systems, Inc. logo

Computer Programs and Systems, Inc.

CPSI

9.19 USD

Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc.

STOK

14.47 USD

SI-BONE, Inc. logo

SI-BONE, Inc.

SIBN

15.73 USD

Y-mAbs Therapeutics, Inc. logo

Y-mAbs Therapeutics, Inc.

YMAB

13.74 USD

Affimed N.V. logo

Affimed N.V.

AFMD

4 USD

Geron Corporation logo

Geron Corporation

GERN

4.51 USD

Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc.

TNGX

10.5 USD

Financials

Numbers are in millions USD

Numbers are in millions USD